The anti-obesity drug tirzepatide, known as Mounjaro (for diabetes) and Zepbound (for obesity), has been found to reduce breast cancer growth linked to obesity in mice.
This study was presented at ENDO 2025 by researchers at the University of Michigan. Obesity increases the risk of breast cancer, and this research explored whether new medications like tirzepatide could help.
In the study, mice were fed a high-fat diet to become obese. At 32 weeks old, they were divided into two groups: one received tirzepatide and the other a placebo. Over 16 weeks, scientists measured their tumor sizes.
Mice treated with tirzepatide lost about 20% of their body weight, mainly due to fat loss. These mice also had smaller breast tumors than the untreated mice.
Researchers found that tumor size was closely linked to body weight and fat levels. These early results suggest that tirzepatide may help improve breast cancer outcomes in people with obesity.
More studies are being done to understand whether the benefits come from the weight loss alone or if the drug also directly affects tumors.
If you care about cancer, please read studies about Researchers find a new cause of cancer and findings of Scientists make a big breakthrough in prostate cancer treatment.
For more about cancer, please read studies about Research finds a new cause of cancer growth and findings of Scientists find the missing link between autoimmune diseases and blood cancer.
Copyright © 2025 Knowridge Science Report. All rights reserved.
